Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11251786 | 0.78 | — | — | |
| SCHEMBL6036659 | 0.78 | TRPA1 (0.32) | TRPA1TRPM8 | |
| SCHEMBL25097368 | 0.77 | — | — | |
| SCHEMBL11490210 | 0.77 | — | — | |
| SCHEMBL21305377 | 0.74 | TRPA1 (0.31) | TRPA1TRPM8 | |
| SCHEMBL11293038 | 0.73 | TRPA1 (0.30) | TRPA1TRPM8 | |
| SCHEMBL14515122 | 0.73 | TRPA1 (0.34) | TRPA1TRPM8 | |
| SCHEMBL1870837 | 0.73 | TRPA1 (0.34) | TRPA1TRPM8 | |
| SCHEMBL719228 | 0.73 | TRPA1 (0.30) | TRPA1TRPM8 | |
| SCHEMBL10767057 | 0.73 | TRPA1 (0.30) | TRPA1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630560-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | NUVALENT, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-3209667-B1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12178901-B2 | Polymer and a topical composition comprising the polymer | CONOPCO, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-12152051-B2 | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-11-26 | — | — | US | disclosed |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240317771-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. | 2024-09-26 | — | — | US | disclosed |
| EP-4408844-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | Nuvalent, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12043626-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | NUVALENT, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-0588915-A1 | AZULENIC RETINOID COMPOUNDS, COMPOSITIONS AND METHODS | UNIVERSITY OF HAWAII (US) | 1994-03-30 | — | — | EP | disclosed |
| EP-0342558-B1 | 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders | SEARLE & CO (US) | 1994-02-02 | — | — | EP | disclosed |
| WO-1993016982-A1 | BICYCLO[2.2.2.]OCTANE DERIVATIVES AS CHOLESTOCYSTOKININ INHIBITORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1993-09-02 | — | — | WO | disclosed |
| US-5235076-A | Anticarcinogenic agents | UNIVERSITY OF HAWAII (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0544442-A2 | Method for producing (+)-estrone derivatives | CHISSO CORPORATION (JP) | 1993-06-02 | — | — | EP | disclosed |
| US-5177109-A | 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders | G. D. SEARLE & CO. (US) | 1993-01-05 | — | — | US | disclosed |
| WO-1992021643-A1 | AZULENIC RETINOID COMPOUNDS, COMPOSITIONS AND METHODS | UNIVERSITY OF HAWAII (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0342558-A2 | 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders | G.D. Searle & Co. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0280771-A1 | 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid derivatives and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-09-07 | — | — | EP | disclosed |
| EP-0031509-B1 | PENEM DERIVATIVES | HOECHST UK LIMITED (GB) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12178901-B2 | Polymer and a topical composition comprising the polymer | KRT18, PUF60, COL1A1 | TRPA1 1782/4885TRPM8 3999/4885 |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | CYP1B1, CYP4B1, CBR1 | TRPA1 4515/4885TRPM8 4833/4885 |
| US-12630560-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | CYP2F1, CYP11B2, CYP7B1 | TRPA1 4562/4885TRPM8 4054/4885 |
| US-20240317771-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | CYP11B2, CYP4A11, CYP11B1 | TRPA1 3548/4885TRPM8 3296/4885 |
| US-12152051-B2 | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | STING1, CGAS, IRF3 | TRPA1 1310/4885TRPM8 502/4885 |
| US-12043626-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | CYP11B2, CYP4A11, CYP11B1 | TRPA1 3548/4885TRPM8 3296/4885 |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | CYP1B1, CYP4B1, CBR1 | TRPA1 4421/4885TRPM8 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.